Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction (MBO-IR)

Clinical Trial of Bile Etiology,Proteomics and Metabonomics of Malignant Biliary Obstruction

To investigate bile culture and susceptibility test in patients with malignant biliary obstruction (MBO) or relation between bile, portal vein or vein culture and biliary infection. Also to get the information of bile metabonomics to find potential tumor marker .Culture of the organism is recognized as the "gold standard" for diagnosis of infection. Our research may be one of the first research on culture and susceptibility test in patients with MBO. The results of the trial research will be benefit to experiential therapy of MBO with biliary infection and diagnosis of MBO.

Study Overview

• Status: Unknown
• Conditions: Malignant Biliary Obstruction

Detailed Description

We will obtain bile sample for culture and susceptibility ,proteomics metabonomics test after PTBD. Also get the blood and urine samples.

• Study Type: Observational
• Enrollment (Anticipated): 300

Contacts and Locations

Study Locations

• China
  • Tianjin
    • Tianjin, Tianjin, China, 300060
      • Recruiting
      • Tianjin Medical University Cancer Institude and Hospital
      • Contact: YU HAIPENG, MD; Phone Number: 13352070835; Email: JIERUKE@YAHOO.COM.CN
      • Principal Investigator: GUO ZHI, professor
      • Sub-Investigator: YU Haipeng, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Malignant obstructive jaundice (MBO)

Description

Inclusion Criteria:

• Those with MBO who can receive Percutaneous Transhepatic Biliary Drainage(PTBD)

Exclusion Criteria:

• Those with MBO who cannot receive Percutaneous Transhepatic Biliary Drainage(PTBD)

Study Plan

How is the study designed?

Collaborators and Investigators

• Sponsor: Tianjin Medical University Cancer Institute and Hospital
• Investigators: Principal Investigator: YU HAI PENG, MD, Tianjin Medical University Cancer Institute and Hospital; Study Chair: GUO ZHI, Professor, Tianjin Medical University Cancer Institute and Hospital

Study record dates

Study Major Dates

• Study Start: December 1, 2009
• Primary Completion (Anticipated): November 1, 2016
• Study Completion (Anticipated): December 1, 2016

Study Registration Dates

• First Submitted: February 21, 2010
• First Submitted That Met QC Criteria: February 22, 2010
• First Posted (Estimate): February 23, 2010

Study Record Updates

• Last Update Posted (Estimate): December 22, 2015
• Last Update Submitted That Met QC Criteria: December 21, 2015
• Last Verified: February 1, 2010

More Information

Terms related to this study

• Keywords: Malignant biliary obstruction (MBO)
• Other Study ID Numbers: TMU-CIH-IR-001; ChiCTR-ONC-00000752 (Registry Identifier: Chinese Clinical Trial Register(http://www.chictr.org))